PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
PBMs made more than $7B marking up specialty generics: FTC
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.
Pharma digs in on changes it wants from Trump administration
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
WebMD8d
New Therapy Brings Hope for Dry AMD Vision Loss
The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.
Clarksville Now15d
Can laser therapy help treat TMJ symptoms? | Ask the Expert
Low-level laser therapy is a non-invasive treatment for TMJ symptoms that uses light to stimulate cellular activity, and it's ...
Forbes1mon
Does PBM Expansion Into Drug Manufacturing Benefit Patients Or Risk Further Anti-Competitive Behaviors?
This preferential treatment harms independent pharmacies and ... there has traditionally been a lack of uptake in biosimilars on PBM formularies, likely due to less favorable PBM rebate models ...
Hosted on MSN23h
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
Yahoo Finance28d
PBM reform looks manageable for CVS Health, says UBS
Based on conversations with industry expects, the Act, while incremental, does not include any adverse new ideas that would materially harm PBM profits, and the text allows enough room and time ...
Benefits Pro25d
President signs anti-shutdown package, with no PBM provisions
Ron Wyden says Elon Musk, an advisor to President Donald Trump who's on track to lead a new Department of Government Efficiency, pushed the PBM provisions out of the package. The new American ...
The Hill29d
PBMs targeted in health deal
The PBM changes would put guardrails on the business practices of the industry, something that’s been a bipartisan priority for years but, until now, never made it to the finish. The package ...
Forbes2mon
Rebate Game Played By PBMs And Drug Makers Limits Biosimilar Competition
Beginning in 2023, five years after their European counterparts, patients in the United States prescribed the autoimmune disease treatment Humira ... the largest PBM in the U.S.—removed Humira ...
Yahoo Finance28d
Bipartisan lawmakers appear 'aligned' on PBM, insurance reform
"They're helping patients kind of manage through the treatment paradigm with respect to which drugs to take, which formulary drugs are on, and kind of managing that whole process. So there is a ...